FDA action counts
| Total FDA actions | 3 |
|---|---|
| Warning letters | 0 |
| Recalls | 3 |
| Approval records | 0 |
| Form 483 inspection citations | 0 |
| Most recent action | July 1, 2026 |
Risk pattern analysis
Argus HQ analysis — not an FDA finding
This section is Argus HQ analysis, not an FDA finding. The Harvard Drug Group LLC has 3 separate FDA recalls on file, more than a single isolated recall event. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.
Enforcement history
On 2026-04-22, Argus HQ recorded a FDA recall for The Harvard Drug Group LLC, rated "high" severity in Argus HQ's classification: The Harvard Drug Group LLC — Class II recall: Memantine Hydrochloride Extended-Release, Capsules, 7 mg, 100 Capsules (10 x 10… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-04-29, Argus HQ recorded a FDA recall for The Harvard Drug Group LLC, rated "high" severity in Argus HQ's classification: The Harvard Drug Group LLC — Class II recall: Omega-3-Acid, Ethyl Esters, Capsules, USP, 1 gram, 50 capsules (5 x 10 unit dose… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-07-01, Argus HQ recorded a FDA recall for The Harvard Drug Group LLC, rated "high" severity in Argus HQ's classification: The Harvard Drug Group LLC — Class II recall: Carton Label: MAJOR, Methylergonovine Maleate Tablets, USP, 0.2 mg, 20 TABLETS (… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. In total, The Harvard Drug Group LLC has 3 FDA events on file with Argus HQ across the sources Argus HQ currently tracks (FDA Warning Letters, recalls, drug/biologic approvals, and Form 483 inspection observations). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Frequently asked questions
- Has The Harvard Drug Group LLC had product recalls?
- Yes, 3 recalls on file. See the full history below for each one.
- Is this FDA enforcement data for The Harvard Drug Group LLC official?
- Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.
- How many FDA actions has The Harvard Drug Group LLC had?
- Argus HQ has recorded 3 FDA events for The Harvard Drug Group LLC: 0 warning letters, 3 recalls, 0 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
- What is the most recent FDA action against The Harvard Drug Group LLC?
- The most recent FDA event Argus HQ has on file for The Harvard Drug Group LLC is dated 2026-07-01, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Every FDA action tied to this company, the week it happens.
Free weekly briefing. Real-time alerts on paid plans.
Related enforcement actions
- The Harvard Drug Group LLC — Class II recall: Carton Label: MAJOR, Methylergonovine Maleate Tablets, USP, 0.2 mg, 20 TABLETS (… →
- The Harvard Drug Group LLC — Class II recall: Omega-3-Acid, Ethyl Esters, Capsules, USP, 1 gram, 50 capsules (5 x 10 unit dose… →
- The Harvard Drug Group LLC — Class II recall: Memantine Hydrochloride Extended-Release, Capsules, 7 mg, 100 Capsules (10 x 10… →
Compare with
Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Actions Against The Harvard Drug Group LLC. Digital Empire LLC. Retrieved from https://argushq.ai/company/the-harvard-drug-group-llc
"FDA Actions Against The Harvard Drug Group LLC." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/company/the-harvard-drug-group-llc.
Argus HQ Research. "FDA Actions Against The Harvard Drug Group LLC." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/company/the-harvard-drug-group-llc.
@misc{argushq_argushq_ai_company_the_harvard_drug_group_llc_2026,
title = {FDA Actions Against The Harvard Drug Group LLC},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/company/the-harvard-drug-group-llc},
note = {Accessed: July 13, 2026}
}Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗

